Masakazu Toi Selected Research

Fulvestrant (Faslodex)

4/2024	Remarkable remission of symptomatic dermatomyositis after curative breast cancer surgery.
11/2023	Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial.
6/2023	Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
1/2023	Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).
1/2023	Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.
5/2022	Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
1/2022	Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
11/2021	MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast Cancer.
9/2021	Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
4/2021	Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masakazu Toi Research Topics

Disease

309	Breast Neoplasms (Breast Cancer) 05/2024 - 01/2002
169	Neoplasms (Cancer) 04/2024 - 01/2002
25	Neoplasm Metastasis (Metastasis) 01/2023 - 11/2002
20	Neutropenia 01/2023 - 01/2002
15	Disease Progression 06/2023 - 01/2002
13	Triple Negative Breast Neoplasms 02/2024 - 01/2013
12	Carcinoma (Carcinomatosis) 07/2018 - 03/2003
8	Diarrhea 06/2023 - 09/2017
7	Fatigue 02/2024 - 01/2003
7	Carcinogenesis 10/2023 - 10/2002
7	Leukopenia 01/2023 - 01/2002
6	Noninfiltrating Intraductal Carcinoma (DCIS) 09/2023 - 01/2011
5	Hypoxia (Hypoxemia) 01/2020 - 10/2003
4	Lymphatic Metastasis 01/2021 - 11/2002
4	Nausea 01/2020 - 10/2007
4	Febrile Neutropenia 05/2018 - 10/2007
3	Pathologic Complete Response 04/2024 - 01/2006
3	Edema (Dropsy) 03/2024 - 01/2005
3	Stomatitis 11/2017 - 05/2014
3	Residual Neoplasm 10/2016 - 03/2012

Drug/Important Bio-Agent (IBA)

70	Hormones (Hormone)IBA 02/2024 - 04/2002
44	Trastuzumab (Herceptin)FDA Link 05/2024 - 01/2004
39	Estrogen ReceptorsIBA 12/2023 - 09/2002
38	ErbB Receptors (EGF Receptor)IBA 03/2024 - 07/2009
28	Biomarkers (Surrogate Marker)IBA 10/2023 - 08/2004
23	abemaciclibIBA 11/2023 - 09/2017
21	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2020 - 03/2003
20	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2002
19	Aromatase InhibitorsIBA 06/2023 - 10/2002
19	human ERBB2 proteinIBA 01/2023 - 03/2007
18	Docetaxel (Taxotere)FDA Link 03/2024 - 01/2003
16	Fulvestrant (Faslodex)FDA Link 04/2024 - 09/2017
16	taxaneIBA 01/2023 - 11/2007
15	AnthracyclinesIBA 03/2024 - 08/2004
15	palbociclibIBA 11/2023 - 12/2015
15	Tamoxifen FDA LinkGeneric 10/2023 - 01/2002
14	Fluorouracil (Carac)FDA LinkGeneric 06/2020 - 04/2002
12	Estrogens (Estrogen)FDA Link 01/2023 - 01/2002
12	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 01/2002
12	Letrozole (Femara)FDA LinkGeneric 04/2021 - 03/2005
11	Capecitabine (Xeloda)FDA Link 01/2022 - 03/2002
11	Progesterone Receptors (Progesterone Receptor)IBA 06/2021 - 09/2002
10	Phenobarbital (Luminal)FDA Link 01/2024 - 09/2010
10	eribulin FDA Link 10/2023 - 09/2017
10	pertuzumabIBA 10/2022 - 01/2017
10	Epirubicin (Ellence)FDA LinkGeneric 04/2020 - 02/2004
10	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 03/2002
10	Aromatase (CYP19)IBA 05/2011 - 07/2002
9	Cyclin-Dependent Kinase 4IBA 05/2024 - 09/2017
9	exemestane (Aromasin)FDA Link 09/2019 - 07/2002
8	Ado-Trastuzumab EmtansineIBA 10/2022 - 01/2017
8	Lapatinib (GW572016)FDA Link 08/2021 - 07/2009
7	Indocyanine Green (Cardio-Green)FDA LinkGeneric 11/2018 - 04/2010
7	Zoledronic Acid (Zometa)FDA Link 04/2018 - 12/2009
6	EnzymesIBA 01/2023 - 02/2002
6	Bevacizumab (Avastin)FDA Link 01/2023 - 03/2012
6	Messenger RNA (mRNA)IBA 07/2018 - 02/2002
6	Transcription Factors (Transcription Factor)IBA 01/2018 - 11/2004
5	Diphosphonates (Bisphosphonates)IBA 06/2024 - 05/2013
5	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2024 - 09/2003
5	Vinorelbine (Navelbine)FDA LinkGeneric 07/2021 - 06/2005
5	Everolimus FDA Link 01/2019 - 05/2014
5	Indicators and Reagents (Reagents)IBA 06/2008 - 04/2002
5	Thymidine PhosphorylaseIBA 03/2005 - 02/2002
4	CytokinesIBA 01/2024 - 02/2011
4	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2023 - 08/2004
4	Immune Checkpoint InhibitorsIBA 12/2022 - 05/2019
4	Taxoids (Taxanes)IBA 10/2022 - 06/2005
4	Epidermal Growth Factor (EGF)IBA 01/2020 - 07/2011
4	Tumor Biomarkers (Tumor Markers)IBA 11/2019 - 04/2004
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 07/2018 - 01/2002
4	IsoflavonesIBA 11/2013 - 11/2005
4	Celecoxib (Celebrex)FDA Link 03/2013 - 09/2003
4	Angiogenesis InhibitorsIBA 01/2012 - 09/2003
4	doxifluridineIBA 02/2005 - 03/2002
3	olaparibIBA 02/2024 - 07/2023
3	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2024 - 08/2004
3	Cisplatin (Platino)FDA LinkGeneric 12/2023 - 01/2002
3	RNA (Ribonucleic Acid)IBA 05/2023 - 01/2013
3	InterferonsIBA 01/2023 - 01/2017
3	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2023 - 06/2018
3	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 01/2018
3	Protein Isoforms (Isoforms)IBA 12/2018 - 01/2002
3	Estradiol (Delestrogen)FDA LinkGeneric 06/2018 - 01/2002
3	TabletsIBA 01/2018 - 01/2016
3	Coloring Agents (Dyes)IBA 12/2017 - 07/2013
3	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 03/2007 - 03/2002

Therapy/Procedure

153	Therapeutics 04/2024 - 01/2002
61	Drug Therapy (Chemotherapy) 03/2024 - 11/2002
36	Neoadjuvant Therapy 10/2022 - 08/2004
12	Radiotherapy 02/2024 - 03/2012
11	Adjuvant Chemotherapy 02/2024 - 03/2003
9	Segmental Mastectomy (Lumpectomy) 09/2023 - 01/2005
7	Immunotherapy 09/2022 - 09/2003
6	Drug Tapering 01/2022 - 01/2002
5	Aftercare (After-Treatment) 03/2024 - 04/2010
4	Chemoprevention 11/2009 - 10/2002
3	Lymph Node Excision (Lymph Node Dissection) 04/2024 - 11/2008
3	Operative Surgical Procedures 12/2023 - 01/2015
3	Retreatment 09/2022 - 01/2018